<DOC>
	<DOCNO>NCT00549757</DOCNO>
	<brief_summary>The purpose study determine whether , patient type 2 diabetes pre-existing disease heart circulatory system and/or kidney , aliskiren target dose 300 mg daily ( compare placebo ) , top conventional treatment , reduce death disease cause heart , circulatory system kidney . AMENDMENT 4 RATIONALE ( MARCH 2012 ) : Protocol amendment 4 serve address data monitoring committee recommendation date 14 Dec 2011 discontinue study treatment participate patient . It also address subsequent Health Authorities request implement 12 month safety follow-up period ( actual duration 9 month average ) post study drug discontinuation .</brief_summary>
	<brief_title>Aliskiren Trial Type 2 Diabetes Using Cardiovascular Renal Disease Endpoints ( Core Extension Phases )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Type 2 diabetes least one following : Macroalbuminuria eGFR ≥30 mL/min/1.73 m2 Microalbuminuria reduce kidney function ( eGFR eGFR ≥30 &lt; 60 mL/min/1.73 m2 ) A history CV disease ( previous MI , previous stroke , heart failure , coronary artery disease , history percutaneous coronary intervention , angiography proven stenosis ≥50 % least one coronary artery reduce kidney function ( eGFR ≥30 &lt; 60 mL/min/1.73 m2 ) Concomitant treatment follow national guideline must include either Angiotensinconvertingenzymeinhibitor ( ACEi ) Angiotensinreceptorblocker ( ARB ) . Type 1 diabetes mellitus Cardiovascular event procedure ≤ 3 month prior Visit 1 Unstable serum creatinine Hypertension : Mean sit systolic blood pressure ( msSBP ) ≥ 135 &lt; 170 mmHg Mean sit diastolic blood pressure ( msDBP ) ≥ 85 &lt; 110 mmHg unless treat least 3 antihypertensive medication Hypertension msSBP ≥ 170 msDBP ≥ 110 mmHg Baseline Serum Potassium &gt; 5.0 mmol/L Patients treat two reninangiotensinaldosteronesystemblockers Patients NYHA class III IV heart failure Known renal artery stenosis Previous randomization AVOID trial ( CSPP100C2201 ) EXCLUSION SPECIFIC TO THE SAFETY FOLLOWUP PERIOD : Aliskiren aliskiren contain fix combination product must use Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>renal morbidity mortality</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>micro-albuminuria</keyword>
	<keyword>macro-albuminuria</keyword>
	<keyword>RAAS</keyword>
	<keyword>renin inhibitor</keyword>
	<keyword>Reduced estimate glomerular filtration rate</keyword>
</DOC>